{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T19:28:24Z","timestamp":1790364504034,"version":"4.1.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIDDK","doi-asserted-by":"publisher","award":["R01DK015015-01-A"],"award-info":[{"award-number":["R01DK015015-01-A"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["UC4 DK104211"],"award-info":[{"award-number":["UC4 DK104211"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P-30 DK 020541"],"award-info":[{"award-number":["P-30 DK 020541"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008871","name":"JDRF","doi-asserted-by":"publisher","award":["2-SRA-2015-62"],"award-info":[{"award-number":["2-SRA-2015-62"]}],"id":[{"id":"10.13039\/100008871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007277","name":"Icahn School of Medicine","doi-asserted-by":"publisher","award":["0285-3980"],"award-info":[{"award-number":["0285-3980"]}],"id":[{"id":"10.13039\/100007277","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R01-GM108911"],"award-info":[{"award-number":["R01-GM108911"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U54-OD020353"],"award-info":[{"award-number":["U54-OD020353"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008299","name":"Dartmouth University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008299","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"NIH\/NIDDK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007878","name":"Diabetes Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007878","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Human Islet Research Network"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejmech.2018.08.007","type":"journal-article","created":{"date-parts":[[2018,8,22]],"date-time":"2018-08-22T18:02:37Z","timestamp":1534960957000},"page":"1005-1016","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic \u03b2-cell proliferation activity"],"prefix":"10.1016","volume":"157","author":[{"given":"Kunal","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Man-Un Ung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew F.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avner","family":"Schlessinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"DeVita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.08.007_bib1","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1742-4658.2010.07956.x","article-title":"Activation, regulation, and inhibition of DYRK1A","volume":"278","author":"Becker","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2018.08.007_bib2","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.cell.2005.03.034","article-title":"Activation-loop autophosphorylation is mediated by a novel transitional intermediate form of DYRKs","volume":"121","author":"Lochhead","year":"2005","journal-title":"Cell (Cambridge, MA, U. S.)"},{"key":"10.1016\/j.ejmech.2018.08.007_bib3","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1111\/febs.12411","article-title":"Mechanism of dual specificity kinase activity of DYRK1A","volume":"280","author":"Walte","year":"2013","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2018.08.007_bib4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2174\/18715273113126660186","article-title":"DYRK1A: a potential drug target for multiple Down syndrome neuropathologies","volume":"13","author":"Becker","year":"2014","journal-title":"CNS Neurol. Disord. - Drug Targets"},{"key":"10.1016\/j.ejmech.2018.08.007_bib5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1742-4658.2010.07955.x","article-title":"The role of DYRK1A in neurodegenerative diseases","volume":"278","author":"Wegiel","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2018.08.007_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/cn300094k","article-title":"Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?","volume":"3","author":"Smith","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2018.08.007_bib7","first-page":"1315","article-title":"DYRK1A kinase inhibitors with emphasis on cancer","volume":"12","author":"Ionescu","year":"2012","journal-title":"Mini rev. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2018.08.007_bib8","article-title":"DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis","volume":"2","author":"Fernandez-Martinez","year":"2015","journal-title":"Mol. Cell. Oncol."},{"key":"10.1016\/j.ejmech.2018.08.007_bib9","first-page":"383","article-title":"A\u00a0high-throughput chemical screen reveals that harmine-mediated inhibition of DYRK1A increases human pancreatic beta cell replication","volume":"21","author":"Wang","year":"2015","journal-title":"Nat. Med. (N. Y., NY, U. S.)"},{"key":"10.1016\/j.ejmech.2018.08.007_bib10","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1038\/ncomms9372","article-title":"Inhibition of DYRK1A and GSK3B induces human \u03b2-cell proliferation","volume":"6","author":"Shen","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2018.08.007_bib11","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.4161\/cc.29250","article-title":"Dyrk1A induces pancreatic \u03b2 cell mass expansion and improves glucose tolerance","volume":"13","author":"Rachdi","year":"2014","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2018.08.007_bib12","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.2337\/db15-1127","article-title":"Inhibition of DYRK1A stimulates human beta-cell proliferation","volume":"65","author":"Dirice","year":"2016","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2018.08.007_bib13","first-page":"1","article-title":"Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity","volume":"62","author":"Becker","year":"1999","journal-title":"Prog. Nucleic Acid Res. Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.08.007_bib14","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1007\/s00018-009-0123-2","article-title":"Function and regulation of Dyrk1A: towards understanding Down syndrome","volume":"66","author":"Park","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2018.08.007_bib15","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms1090","article-title":"Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A","volume":"1","author":"Ogawa","year":"2010","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2018.08.007_bib16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.4155\/fmc-2016-0013","article-title":"DYRK1A inhibition as potential treatment for Alzheimer's disease","volume":"8","author":"Stotani","year":"2016","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib17","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1172\/JCI63623","article-title":"Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth","volume":"123","author":"Pozo","year":"2013","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ejmech.2018.08.007_bib18","doi-asserted-by":"crossref","first-page":"6268","DOI":"10.1111\/j.1742-4658.2008.06751.x","article-title":"DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine","volume":"275","author":"Seifert","year":"2008","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2018.08.007_bib19","series-title":"CC-401 Promotes \u0392-Cell Replication via Pleiotropic Consequences of DYRK1A\/B Inhibition, Endocrinology","author":"Abdolazimi","year":"2018"},{"key":"10.1016\/j.ejmech.2018.08.007_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0004606","article-title":"Green tea polyphenols rescue of brain defects induced by overexpression of DYRK1A","volume":"4","author":"Guedj","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.08.007_bib21","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/bj20021535","article-title":"The specificities of protein kinase inhibitors: an update","volume":"371","author":"Bain","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2018.08.007_bib22","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1021\/jm301034u","article-title":"Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B","volume":"55","author":"Tahtouh","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib23","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.euroneuro.2015.03.018","article-title":"Leucettine L41, a DYRK1A-preferential DYRKs\/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric A\u03b225-35 peptide administration in mice","volume":"25","author":"Naert","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejmech.2018.08.007_bib24","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1042\/BJ20090069","article-title":"Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2","volume":"421","author":"Cozza","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2018.08.007_bib25","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0029-1186226","article-title":"Two new peltogynoids from Acacia nilotica Delile with kinase inhibitory activity","volume":"76","author":"Ahmadu","year":"2010","journal-title":"Planta Med."},{"key":"10.1016\/j.ejmech.2018.08.007_bib26","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00018-011-0758-7","article-title":"Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A","volume":"69","author":"Sarno","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2018.08.007_bib27","series-title":"Generation of Potent and Selective Kinase Inhibitors by Combinatorial Biosynthesis of Glycosylated Indolocarbazoles","first-page":"4118","author":"Sanchez","year":"2009"},{"key":"10.1016\/j.ejmech.2018.08.007_bib28","doi-asserted-by":"crossref","first-page":"9569","DOI":"10.1021\/jm401049v","article-title":"Development of DANDYs, new 3,5-Diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity","volume":"56","author":"Gourdain","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib29","doi-asserted-by":"crossref","first-page":"11391","DOI":"10.1038\/ncomms11391","article-title":"Selective inhibition of the kinase DYRK1A by targeting its folding process","volume":"7","author":"Kii","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2018.08.007_bib30","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.bmcl.2009.02.062","article-title":"QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors","volume":"19","author":"Koo","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.007_bib31","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1016\/j.bmcl.2006.04.042","article-title":"Putative therapeutic agents for the learning and memory deficits of people with Down syndrome","volume":"16","author":"Kim","year":"2006","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.007_bib32","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1016\/j.bmcl.2011.02.114","article-title":"Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)","volume":"21","author":"Rosenthal","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.007_bib33","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1021\/jm200464w","article-title":"Synthesis, protein kinase inhibitory potencies, and in\u00a0vitro antiproliferative activities of meridianin derivatives","volume":"54","author":"Giraud","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib34","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/jm700940h","article-title":"Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2\/cyclin A\/Meriolin complex","volume":"51","author":"Echalier","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib35","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1016\/j.bmc.2009.05.017","article-title":"Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins","volume":"17","author":"Akue-Gedu","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib36","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1016\/j.ejmech.2011.08.048","article-title":"Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents","volume":"46","author":"Kassis","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib37","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejmech.2012.01.040","article-title":"Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues : a novel DYRK1A inhibitor class","volume":"49","author":"Neagoie","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib38","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/jm501994d","article-title":"10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A","volume":"58","author":"Falke","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib39","article-title":"Design and synthesis of thiazolo[5,4-f]quinazolines as DYRK1A inhibitors, part I","volume":"19","author":"Foucourt","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.08.007_bib40","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jnc.13018","article-title":"A\u00a0novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in\u00a0vitro","volume":"133","author":"Coutadeur","year":"2015","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib41","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1073\/pnas.1201149109","article-title":"Adenosine kinase inhibition selectively promotes rodent and porcine islet \u03b2-cell replication","volume":"109","author":"Annes","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2018.08.007_bib42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1021\/cb500696t","article-title":"DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-ii inhibitors","volume":"10","author":"Ung","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.08.007_bib43","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type II binding mode: a privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.08.007_bib44","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2018.08.007_bib45","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.bmcl.2013.10.055","article-title":"Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors","volume":"23","author":"Anderson","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.007_bib46","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/jm501994d","article-title":"10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A","volume":"58","author":"Falke","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib47","doi-asserted-by":"crossref","first-page":"9814","DOI":"10.1021\/acs.jmedchem.6b01086","article-title":"Probing the ATP-binding pocket of protein kinase DYRK1A with benzothiazole fragment molecules","volume":"59","author":"Rothweiler","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib48","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1006\/jmbi.1993.1626","article-title":"Comparative protein modelling by satisfaction of spatial restraints","volume":"234","author":"Sali","year":"1993","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.08.007_bib49","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1110\/ps.062416606","article-title":"Statistical potential for assessment and prediction of protein structures","volume":"15","author":"Shen","year":"2006","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2018.08.007_bib50","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1110\/ps.036061.108","article-title":"How well can the accuracy of comparative protein structure models be predicted?","volume":"17","author":"Eramian","year":"2008","journal-title":"Protein Sci."},{"key":"10.1016\/j.ejmech.2018.08.007_bib51","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1021\/acsmedchemlett.6b00044","article-title":"Design and development of a series of potent and selective type II inhibitors of CDK8","volume":"7","author":"Bergeron","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.007_bib52","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jmb.2011.07.020","article-title":"The structure of CDK8\/CycC implicates specificity in the CDK\/cyclin family and reveals interaction with a deep pocket binder","volume":"412","author":"Schneider","year":"2011","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.08.007_bib53","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/ci3001277","article-title":"ZINC: a free tool to discover chemistry for biology","volume":"52","author":"Irwin","year":"2012","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2018.08.007_bib54","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1021\/ci9003706","article-title":"Molecular docking screens using comparative models of proteins","volume":"49","author":"Fan","year":"2009","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2018.08.007_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/156802610790232279","article-title":"Emerging methods for ensemble-based virtual screening","volume":"10","author":"Amaro","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.007_bib56","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/nchembio.1867","article-title":"The promise and peril of chemical probes","volume":"11","author":"Arrowsmith","year":"2015","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.08.007_bib57","unstructured":"LanthaScreen\u00ae Eu Kinase Binding Assay - Customer Protocol and Assay Conditions Documents located at https:\/\/www.thermofisher.com\/us\/en\/home\/industrial\/pharma-biopharma\/drug-discovery-development\/target-and-lead-identification-and-validation\/kinasebiology\/kinase-activity-assays\/lanthascreentm-eu-kinase-binding-assay.html."},{"key":"10.1016\/j.ejmech.2018.08.007_bib58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A\u00a0small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2018.08.007_bib59","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/hlca.201300077","article-title":"Unexpected ring enlargement of 2-Hydrazono-2,3-dihydro-1,3-thiazoles to 1,3,4-thiadiazines","volume":"97","author":"Pfeiffer","year":"2014","journal-title":"Helv. Chim. Acta"},{"key":"10.1016\/j.ejmech.2018.08.007_bib60","series-title":"Preparation of Piperidine Derivatives as Subtype Selective N-methyl-d-aspartate Antagonists Useful in the Treatment of Cerebral Vascular Disorders","first-page":"154","author":"Kornberg","year":"2002"},{"key":"10.1016\/j.ejmech.2018.08.007_bib61","series-title":"Efficient Conversion of Nitriles to Amides with Basic Hydrogen Peroxide in Dimethyl Sulfoxide, Synthesis","first-page":"949","author":"Katritzky","year":"1989"},{"key":"10.1016\/j.ejmech.2018.08.007_bib62","doi-asserted-by":"crossref","first-page":"12256","DOI":"10.1002\/anie.201303207","article-title":"Profound methyl effects in drug discovery and a call for new C-H methylation reactions","volume":"52","author":"Schoenherr","year":"2013","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2018.08.007_bib63","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1021\/cb500129t","article-title":"Exploration of type ii binding mode: a privileged approach for kinase inhibitor focused drug discovery?","volume":"9","author":"Zhao","year":"2014","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2018.08.007_bib64","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1006\/jmbi.2000.4042","article-title":"T-Coffee: A novel method for fast and accurate multiple sequence alignment","volume":"302","author":"Notredame","year":"2000","journal-title":"J.\u00a0Mol. Biol."},{"key":"10.1016\/j.ejmech.2018.08.007_bib65","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1021\/ct500381c","article-title":"POVME 2.0: an enhanced tool for determining pocket shape and volume characteristics","volume":"10","author":"Durrant","year":"2014","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2018.08.007_bib66","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1021\/ci100436p","article-title":"FRED pose prediction and virtual screening accuracy","volume":"51","author":"McGann","year":"2011","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2018.08.007_bib67","series-title":"Release 2015-3: Maestro, LigPrep","author":"Schr\u00f6dinger","year":"2017"},{"key":"10.1016\/j.ejmech.2018.08.007_bib68","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1021\/acs.jctc.5b00864","article-title":"OPLS3: a force field providing broad coverage of drug-like small molecules and proteins","volume":"12","author":"Harder","year":"2016","journal-title":"J.\u00a0Chem. Theor. Comput."},{"key":"10.1016\/j.ejmech.2018.08.007_bib69","doi-asserted-by":"crossref","first-page":"15810","DOI":"10.1073\/pnas.1106030108","article-title":"Structure-based discovery of prescription drugs that interact with the norepinephrine transporter, NET","volume":"108","author":"Schlessinger","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2018.08.007_bib70","unstructured":"KINOMEscan\u00ae Assay- Customer Protocol and Assay Conditions Documents located at https:\/\/www.discoverx.com\/technologies-platforms\/competitive-binding-technology\/kinomescan-technology-platform."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418306652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418306652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:56:18Z","timestamp":1759326978000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418306652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":70,"alternative-id":["S0223523418306652"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.08.007","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic \u03b2-cell proliferation activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.08.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}